"Obtaining CAP accreditation further demonstrates the integrity of our lab, qualifications of our personnel, and the rigor with which Decipher Post-Op and Biopsy testing is performed," said Doug Dolginow, M.D., chief executive officer of GenomeDx. "We believe our genomic tests, being developed in collaboration with the urologic oncology community through Decipher GRIDTM, facilitate better decision-making at multiple stages of prostate cancer. Clinicians utilizing our platform now have additional assurance that the results our tests will be reliable and of the highest quality."
About CAP and the CAP Laboratory Accreditation Program
As the leading organization with more than 18,000 board-certified pathologists, CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP Laboratory Improvement Programs, initiated 65 years ago, currently have customers in more than 100 countries, accrediting 7,700 laboratories and providing proficiency testing to 20,000 laboratories worldwide.
The CAP Laboratory Accreditation Program is designed to ensure the highest standard of care for all laboratory patients. During the accreditation process, inspectors closely examine the clinical laboratory's records and quality control procedures. They also assess the laboratory's staff qualifications, equipment, facilities, safety program and record, and overall management to ensure it meets CAP's highest standards of quality, accuracy and consistency. The goal of the CAP program is to improve patient safety by advancing the quality of pathology and laboratory services through education and strict standards.
About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California.
Learn more at www.GenomeDx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedx-biosciences-receives-accreditation-from-college-of-american-pathologists-300294328.html
SOURCE GenomeDx Biosciences